No abstract

Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

A median follow-up period was 4.9 years (range, 0.34 to 27.6 years). PS was estimated using factors including age, sex, T stage, N stage, radiotherapy techniques and primary sites. Propensity score (PS) matching and inverse probability of treatment weighting (IPTW) were used to estimate and compare survival outcomes. Results: Five-year overall survival (OS), disease-free survival (DFS), locoregional control (LRC), distant metastasis-free survival (DMFS) of unmodified cohort were 75.7%, 31.4%, 66.3%, 34.2% (definitive RT) and 86.8%, 49.5%, 79.7%, 55.9% (surgery + PORT). These treatment outcomes were significantly different between two groups (p<0.05). In the PS-matched cohort, differences between the treatment outcomes were not significant.